ES3017686T3 - Ciforadent alone or in combination with atezolizumab for use in treating cancer - Google Patents

Ciforadent alone or in combination with atezolizumab for use in treating cancer Download PDF

Info

Publication number
ES3017686T3
ES3017686T3 ES16880133T ES16880133T ES3017686T3 ES 3017686 T3 ES3017686 T3 ES 3017686T3 ES 16880133 T ES16880133 T ES 16880133T ES 16880133 T ES16880133 T ES 16880133T ES 3017686 T3 ES3017686 T3 ES 3017686T3
Authority
ES
Spain
Prior art keywords
substituted
unsubstituted
cancer
receptor antagonist
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16880133T
Other languages
English (en)
Spanish (es)
Inventor
Stephen Willingham
Richard Miller
Po Ho
Lan Mccaffery
Andrew Hotson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corvus Pharmaceuticals Inc
Original Assignee
Corvus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvus Pharmaceuticals Inc filed Critical Corvus Pharmaceuticals Inc
Application granted granted Critical
Publication of ES3017686T3 publication Critical patent/ES3017686T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES16880133T 2015-12-24 2016-12-22 Ciforadent alone or in combination with atezolizumab for use in treating cancer Active ES3017686T3 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562387383P 2015-12-24 2015-12-24
US201662324211P 2016-04-18 2016-04-18
US201662350602P 2016-06-15 2016-06-15
US201662421171P 2016-11-11 2016-11-11
US201662421109P 2016-11-11 2016-11-11
PCT/US2016/068459 WO2017112917A1 (en) 2015-12-24 2016-12-22 Methods of treating cancer

Publications (1)

Publication Number Publication Date
ES3017686T3 true ES3017686T3 (en) 2025-05-13

Family

ID=59091273

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16880133T Active ES3017686T3 (en) 2015-12-24 2016-12-22 Ciforadent alone or in combination with atezolizumab for use in treating cancer

Country Status (13)

Country Link
US (2) US10912776B2 (enExample)
EP (1) EP3393475B1 (enExample)
JP (1) JP6847958B2 (enExample)
KR (1) KR20180103918A (enExample)
CN (1) CN108883107A (enExample)
AU (1) AU2016379425B2 (enExample)
CA (1) CA3009527C (enExample)
EA (1) EA201891509A1 (enExample)
ES (1) ES3017686T3 (enExample)
IL (1) IL260199B (enExample)
MX (1) MX391382B (enExample)
WO (1) WO2017112917A1 (enExample)
ZA (1) ZA201804227B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016379425B2 (en) 2015-12-24 2021-11-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
WO2018187484A1 (en) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
BR112020000962A2 (pt) 2017-07-18 2020-07-14 Nuvation Bio Inc. compostos de 1,8-naftiridinona e usos dos mesmos
JP2020527588A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． アデノシンアンタゴニストとしてのヘテロ環式化合物
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
AU2018317390A1 (en) * 2017-08-14 2020-04-02 Cytodigm, Inc. Microparticle formulations of adenosine receptor antagonists for treating cancer
CN109662966A (zh) * 2017-10-16 2019-04-23 北京莱科金基因科技有限责任公司 伊曲茶碱在制备用于肿瘤治疗的药物中的用途
US20200261462A1 (en) * 2017-11-06 2020-08-20 Corvus Pharmaceuticals, Inc. Combination therapy for cancer treatment
CN111565722A (zh) * 2017-11-06 2020-08-21 科尔沃斯制药股份有限公司 用于癌症治疗的腺苷路径抑制剂
JP2021512860A (ja) * 2018-02-01 2021-05-20 コーバス・ファーマシューティカルズ・インコーポレイテッド 薬学的製剤
EP3520782A3 (en) 2018-02-01 2019-11-13 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations containing adenosine a2a receptor antagonists
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2019233994A1 (en) 2018-06-04 2019-12-12 Exscientia Ltd Pyrazolopyrimidine compounds as adenosine receptor antagonists
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
CA3106041A1 (en) * 2018-07-12 2020-01-16 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
JP2021531751A (ja) 2018-07-12 2021-11-25 コーバス・ファーマシューティカルズ・インコーポレイテッド アデノシン経路活性化を有する癌を検出および治療するための方法
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
BR112021013936A2 (pt) 2019-01-18 2021-09-21 Nuvation Bio Inc. Compostos heterocíclicos como antagonistas de adenosina
CN113939291A (zh) 2019-01-18 2022-01-14 诺维逊生物股份有限公司 1,8-萘啶酮化合物及其用途
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
KR20200105246A (ko) * 2019-02-28 2020-09-07 한미약품 주식회사 아데노신 수용체 길항제로서 신규 화합물 및 이를 포함하는 약학 조성물
CN112479956A (zh) * 2019-07-30 2021-03-12 杭州阿诺生物医药科技有限公司 一种用于制备腺苷受体抑制剂中间体的方法
AU2020394514A1 (en) * 2019-11-26 2022-07-07 Astrazeneca Ab Methods of treating cancer
BR112022011235A2 (pt) * 2019-12-09 2022-12-13 Twist Bioscience Corp Bibliotecas de variantes de ácido nucleico para receptores de adenosina
KR20220150281A (ko) * 2020-01-03 2022-11-10 인사이트 코포레이션 A2a/a2b 및 pd-1/pd-l1 억제제를 포함하는 조합 요법
KR20230147617A (ko) * 2021-01-21 2023-10-23 트위스트 바이오사이언스 코포레이션 아데노신 수용체에 관한 방법 및 조성물
CN116898858B (zh) * 2023-08-11 2025-09-23 锦州医科大学 一种治疗非小细胞肺癌的药物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE204902T1 (de) 1990-06-29 2001-09-15 Large Scale Biology Corp Melaninproduktion durch transformierte mikroorganismen
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
US7767685B2 (en) 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
CN116059219A (zh) 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
AU2016379425B2 (en) * 2015-12-24 2021-11-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
WO2018187484A1 (en) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
CN111565722A (zh) * 2017-11-06 2020-08-21 科尔沃斯制药股份有限公司 用于癌症治疗的腺苷路径抑制剂
JP2021512860A (ja) * 2018-02-01 2021-05-20 コーバス・ファーマシューティカルズ・インコーポレイテッド 薬学的製剤

Also Published As

Publication number Publication date
EP3393475A1 (en) 2018-10-31
JP6847958B2 (ja) 2021-03-24
AU2016379425A1 (en) 2018-07-12
US20210154199A1 (en) 2021-05-27
EP3393475C0 (en) 2025-02-05
US20190076433A1 (en) 2019-03-14
US10912776B2 (en) 2021-02-09
EP3393475A4 (en) 2019-08-14
MX391382B (es) 2025-03-21
EP3393475B1 (en) 2025-02-05
US12023337B2 (en) 2024-07-02
WO2017112917A8 (en) 2018-07-26
ZA201804227B (en) 2022-07-27
KR20180103918A (ko) 2018-09-19
CA3009527A1 (en) 2017-06-29
AU2016379425B2 (en) 2021-11-11
CA3009527C (en) 2024-01-09
JP2019503365A (ja) 2019-02-07
CN108883107A (zh) 2018-11-23
IL260199A (en) 2018-07-31
IL260199B (en) 2022-01-01
EA201891509A1 (ru) 2019-01-31
WO2017112917A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
US12023337B2 (en) Methods of treating cancer
US20240115700A1 (en) Cancer treatment combinations
CN111565722A (zh) 用于癌症治疗的腺苷路径抑制剂
US20230192846A1 (en) Anti-ror-2 antibodies and methods of use
US20190022096A1 (en) Methods of treating cancer
US20210023238A1 (en) Triptolide antibody conjugates
JP2025063134A (ja) 化学療法抵抗性がんの組合せ処置
CN111587113A (zh) 用于癌症治疗的组合疗法
CA3029003C (en) Cancer treatment combinations
HK1263152A1 (en) Ciforadent alone or in combination with atezolizumab for use in treating cancer
HK1263152B (en) Ciforadent alone or in combination with atezolizumab for use in treating cancer
US12617845B2 (en) SMC1A antibodies and uses thereof
NZ743653A (en) Methods of treating cancer
WO2022055940A1 (en) Vista inhibitors